• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用群体模型对乳腺癌患者内源性粒细胞集落刺激因子进行表征及其与化疗诱导的中性粒细胞减少的负相关关系

Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling.

作者信息

Quartino Angelica L, Karlsson Mats O, Lindman Henrik, Friberg Lena E

机构信息

The Pharmacometrics Research Group, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 75124, Uppsala, Sweden,

出版信息

Pharm Res. 2014 Dec;31(12):3390-403. doi: 10.1007/s11095-014-1429-9. Epub 2014 Jun 12.

DOI:10.1007/s11095-014-1429-9
PMID:24919931
Abstract

PURPOSE

Neutropenia is a severe adverse-event of chemotherapeutics. Neutrophils (ANC) are mainly regulated by granulocyte colony stimulating factor (G-CSF). The aim was to characterize the dynamics between endogenous G-CSF and ANC over time following chemotherapy.

METHODS

Endogenous G-CSF and ANC were monitored in forty-nine breast cancer patients treated with sequential adjuvant 5-fluorouracil-epirubicin-cyclophosphamide and docetaxel.

RESULTS

During treatment courses ANC was transiently decreased and was reflected in an endogenous G-CSF increase, which was well described by a semi-mechanistic model including control mechanisms; when G-CSF concentrations increased the proliferation rate increased and the bone maturation time reduced for ANC. Subsequently, ANC in the circulation increased leading to increased elimination of G-CSF. Additionally, a non-specific elimination for G-CSF was quantified. The ANC-dependent elimination contributed to 97% at baseline and 49% at an ANC of 0.1 · 10(9)/L to the total G-CSF elimination.

CONCLUSION

The integrated G-CSF-myelosuppression model captured the initial rise in endogenous G-CSF following chemotherapy-induced neutropenia and the return to baseline of G-CSF and ANC. The model supported the self-regulatory properties of the system and may be a useful tool for further characterization of the biological system and in optimization of chemotherapy treatment.

摘要

目的

中性粒细胞减少是化疗药物的一种严重不良事件。中性粒细胞(ANC)主要受粒细胞集落刺激因子(G-CSF)调节。本研究旨在描述化疗后内源性G-CSF与ANC随时间变化的动态关系。

方法

对49例接受序贯辅助5-氟尿嘧啶-表柔比星-环磷酰胺及多西他赛治疗的乳腺癌患者监测内源性G-CSF和ANC。

结果

在治疗过程中,ANC短暂下降,这反映在内源性G-CSF升高上,这一过程可用一个包含控制机制的半机制模型很好地描述;当G-CSF浓度升高时,ANC的增殖速率增加,骨髓成熟时间缩短。随后,循环中的ANC增加,导致G-CSF的清除增加。此外,还对G-CSF的非特异性清除进行了量化。在基线时,ANC依赖性清除占G-CSF总清除量的97%,当ANC为0.1·10⁹/L时,该比例为49%。

结论

整合的G-CSF-骨髓抑制模型捕捉到了化疗诱导的中性粒细胞减少后内源性G-CSF的初始升高以及G-CSF和ANC恢复至基线水平的过程。该模型支持了该系统的自我调节特性,可能是进一步表征生物系统及优化化疗治疗的有用工具。

相似文献

1
Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling.利用群体模型对乳腺癌患者内源性粒细胞集落刺激因子进行表征及其与化疗诱导的中性粒细胞减少的负相关关系
Pharm Res. 2014 Dec;31(12):3390-403. doi: 10.1007/s11095-014-1429-9. Epub 2014 Jun 12.
2
Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.粒细胞集落刺激因子(G-CSF)支持的剂量递增氟尿嘧啶/表柔比星/环磷酰胺(FEC)疗法作为乳腺癌术后辅助治疗的急性血液学可行性。
Anticancer Res. 1999 Sep-Oct;19(5C):4429-34.
3
Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia.早期乳腺癌的全剂量化疗,无论绝对中性粒细胞计数如何,且不使用 G-CSF,并不增加化疗引起的发热性中性粒细胞减少症。
Support Care Cancer. 2013 Oct;21(10):2727-31. doi: 10.1007/s00520-013-1851-2. Epub 2013 May 26.
4
Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.一项随机双盲前瞻性试验,旨在评估沙格司亭与安慰剂在II期和III期乳腺癌的中剂量氟尿嘧啶、多柔比星和环磷酰胺辅助化疗方案中的效果。
J Clin Oncol. 1996 Nov;14(11):2976-83. doi: 10.1200/JCO.1996.14.11.2976.
5
Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.在接受多西他赛-环磷酰胺化疗的患者中,长效 G-CSF(非格司亭)固定剂量的合理性。
J Clin Pharmacol. 2021 Feb;61(2):204-210. doi: 10.1002/jcph.1723. Epub 2020 Aug 21.
6
Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer.乳腺癌辅助性FEC化疗患者的预处理血液学实验室值可预测是否会出现过度骨髓抑制。
Ann Oncol. 2009 Jan;20(1):34-40. doi: 10.1093/annonc/mdn560. Epub 2008 Aug 13.
7
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer.在早期乳腺癌辅助 tailor 剂量密集化疗的 PANTHER III 期研究中出现的中性粒细胞减少并发症。
Acta Oncol. 2020 Jan;59(1):75-81. doi: 10.1080/0284186X.2019.1670353. Epub 2019 Oct 4.
8
Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.对于乳腺癌辅助化疗后出现长期中性粒细胞减少的患者,为期五天的粒细胞集落刺激因子疗程是维持剂量强度的一种安全且具有成本效益的方案。
J Clin Oncol. 1996 May;14(5):1573-80. doi: 10.1200/JCO.1996.14.5.1573.
9
Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).左亚叶酸、5-氟尿嘧啶、环磷酰胺以及递增剂量表柔比星联合粒细胞集落刺激因子支持治疗局部晚期和/或转移性乳腺癌:意大利南部肿瘤协作组(GOIM)的一项Ⅰ-Ⅱ期研究
Br J Cancer. 1995 Nov;72(5):1245-50. doi: 10.1038/bjc.1995.494.
10
Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.粒细胞集落刺激因子对 FOLFIRINOX 诱导的中性粒细胞减少症预防的影响:基于群体药代动力学/药效学的方法。
Br J Clin Pharmacol. 2020 Dec;86(12):2473-2485. doi: 10.1111/bcp.14356. Epub 2020 Jun 5.

引用本文的文献

1
Exploring optimal administration timing of pegylated recombinant human granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in early breast cancer treated with pharmorubicin and endoxan: a prospective randomized controlled clinical trial.探讨多柔比星和环磷酰胺化疗诱导的早期乳腺癌中性粒细胞减少症中聚乙二醇化重组人粒细胞集落刺激因子最佳给药时机的前瞻性随机对照临床试验。
BMC Cancer. 2024 Nov 12;24(1):1387. doi: 10.1186/s12885-024-13156-y.
2
Effect of lithium on chemotherapy-induced neutropenia in Egyptian breast cancer patients; a prospective clinical study.锂对埃及乳腺癌患者化疗引起的中性粒细胞减少症的影响:一项前瞻性临床研究。
Cancer Chemother Pharmacol. 2024 Jun;93(6):541-554. doi: 10.1007/s00280-023-04620-w. Epub 2024 Feb 7.
3

本文引用的文献

1
Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.基于模型的方法来描述卡铂治疗癌症患者时 G-CSF 的作用。
Pharm Res. 2013 Nov;30(11):2795-807. doi: 10.1007/s11095-013-1099-z. Epub 2013 Jun 26.
2
Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor.不同半机械化学疗相关性中性粒细胞减少症模型的比较:BI 2536(一种 Plk-1 抑制剂)的应用。
Cancer Chemother Pharmacol. 2011 Dec;68(6):1517-27. doi: 10.1007/s00280-011-1647-3. Epub 2011 Apr 24.
3
A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model.
Semimechanistic pharmacokinetic-pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy.化疗后儿童患者培非格司亭的半机械药代动力学-药效学模型。
CPT Pharmacometrics Syst Pharmacol. 2023 Sep;12(9):1319-1334. doi: 10.1002/psp4.13012. Epub 2023 Aug 9.
4
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development.肿瘤临床药物开发中建模和模拟实践的全面监管和行业审查。
J Pharmacokinet Pharmacodyn. 2023 Jun;50(3):147-172. doi: 10.1007/s10928-023-09850-2. Epub 2023 Mar 4.
5
Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies.阿伐度胺诱导的中性粒细胞减少症的定量系统药理学建模助力虚拟临床剂量和给药方案探索研究。
AAPS J. 2021 Aug 27;23(5):103. doi: 10.1208/s12248-021-00623-8.
6
An in vitro quantitative systems pharmacology approach for deconvolving mechanisms of drug-induced, multilineage cytopenias.一种体外定量系统药理学方法,用于剖析药物诱导的多谱系血细胞减少症的作用机制。
PLoS Comput Biol. 2020 Jul 23;16(7):e1007620. doi: 10.1371/journal.pcbi.1007620. eCollection 2020 Jul.
7
Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis.PEG 化 G-CSF 是否优于乳腺癌患者接受化疗时的 G-CSF?系统评价和荟萃分析。
Support Care Cancer. 2020 Nov;28(11):5085-5097. doi: 10.1007/s00520-020-05603-w. Epub 2020 Jul 3.
8
Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine.群体药代动力学和药代动力学/药效学分析的先验信息:概述及 NONMEM PRIOR 子程序重点指导
J Pharmacokinet Pharmacodyn. 2020 Oct;47(5):431-446. doi: 10.1007/s10928-020-09695-z. Epub 2020 Jun 13.
9
Importance of Stability Analysis When Using Nonlinear Semimechanistic Models to Describe Drug-Induced Hematotoxicity.当使用非线性半机械模型来描述药物引起的血液毒性时,稳定性分析的重要性。
CPT Pharmacometrics Syst Pharmacol. 2020 Sep;9(9):498-508. doi: 10.1002/psp4.12514. Epub 2020 Jul 8.
10
Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.粒细胞集落刺激因子对 FOLFIRINOX 诱导的中性粒细胞减少症预防的影响:基于群体药代动力学/药效学的方法。
Br J Clin Pharmacol. 2020 Dec;86(12):2473-2485. doi: 10.1111/bcp.14356. Epub 2020 Jun 5.
采用半机理骨髓抑制模型分析多西紫杉醇给药后白细胞和中性粒细胞时间进程的同步分析。
Invest New Drugs. 2012 Apr;30(2):833-45. doi: 10.1007/s10637-010-9603-3. Epub 2010 Dec 14.
4
Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed.预测抗癌药物 BI 2536(一种 Plk1 抑制剂)与培美曲塞联合治疗的中性粒细胞减少相关作用。
Clin Pharmacol Ther. 2010 Nov;88(5):660-7. doi: 10.1038/clpt.2010.148. Epub 2010 Oct 6.
5
Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations.健康成年人静脉注射和皮下注射非格司亭的药代动力学-药效学群体建模。
J Clin Pharmacol. 2010 Sep;50(9 Suppl):101S-112S. doi: 10.1177/0091270010376966.
6
Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information.基于模型的化疗中性粒细胞指导剂量调整:不同类型和数量信息预测结果的评估。
Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):234-42. doi: 10.1111/j.1742-7843.2009.00520.x. Epub 2009 Dec 30.
7
Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations.健康成年人静脉注射和皮下注射粒细胞集落刺激因子的群体药代动力学模型研究。
Clin Pharmacokinet. 2009;48(12):817-26. doi: 10.2165/11318090-000000000-00000.
8
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.化疗诱导的骨髓抑制在个体间的变异性与在不同时间点的变异性之间存在局限性。
Cancer Chemother Pharmacol. 2010 Apr;65(5):839-48. doi: 10.1007/s00280-009-1089-3. Epub 2009 Aug 14.
9
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.接受化疗的成年癌症患者中性粒细胞减少事件的风险及发生时间:一项全国肿瘤学实践前瞻性研究的结果
J Natl Compr Canc Netw. 2008 Feb;6(2):109-18. doi: 10.6004/jnccn.2008.0012.
10
Population pharmacokinetic and pharmacodynamic analysis for time courses of docetaxel-induced neutropenia in Japanese cancer patients.日本癌症患者多西他赛诱导的中性粒细胞减少症病程的群体药代动力学和药效学分析。
Cancer Sci. 2007 Dec;98(12):1985-92. doi: 10.1111/j.1349-7006.2007.00615.x. Epub 2007 Sep 19.